RISK ASSESSMENT FOR CUTANEOUS ADVERSE DRUG REACTIONS FROM ANTIRETROVIRAL AGENT

ABSTRACT

The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.

(No suitable figure)